12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pomalidomide regulatory update

FDA cancelled a Nov. 8 meeting of the Oncologic Drugs Advisory Committee (ODAC) that was scheduled to discuss an NDA from Celgene for pomalidomide and an sNDA from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) for Exjade ...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >